Liu W, Liu Song Y, Wang X. Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019[J] Aging (Albany NY). 2022 ,14(7):3175-3190.
[2]
Tilly H, Morschhauser F, Sehn L H, et al.Polatuzumabvedotin in previously untreated diffuse large b-cell lymphoma[J] N Engl J Med, 2022,386(4):351-363.
[3]
Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 Bispecific T-cell-engaging antibody, in relapsed or refractory large B-Cell lymphoma: dose expansion in a phase i/ii trial[J]J Clin Oncol,2023,41(12):2238-2247.
[4]
Yagi Y, Kanemasa Y, Sasaki Y, et al. Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: a retrospective study[J]Cancer Med,2023,12(17):17808-17821.
[5]
Freites M A,Santana N, Arias S S, et al. Using the common terminology criteria for adverse events (ctcae-version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr (Engl Ed), 2021,112(1):90-92.
[6]
Sawalha Y. Relapsed/refractory diffuse large B-Cell Lymphoma: a look at the approved and emerging therapies[J]. J Pers Med,2021,11(12):1345.
2025, Vol. 36 
